What We Did

• Pre-Investment and Strategic Advisory:

  Our feasibility study analyzed Egypt's parenteral market (valued at $280 Million with 15% CAGR), import substitution potential, and export opportunities to North African and Middle Eastern markets. We conducted site selection across three pharmaceutical zones, evaluating 10th of Ramadan City, 6th of October City, and Borg El Arab, ultimately recommending 10th of Ramadan for established pharmaceutical infrastructure, proximity to Cairo's medical institutions, and streamlined regulatory coordination with pharmaceutical cluster authorities. CapEx planning of EGP 950 Million covered aseptic manufacturing lines, clean room infrastructure, quality control laboratories, and compliance documentation. We facilitated applications for EDA manufacturing licenses, environmental permits, and initiated pre-approval discussions with WHO Pre-qualification Programme for export markets.

• Engineering & Design Services:

  IMARC designed a comprehensive GMP-compliant facility featuring ISO Class 5 (Grade A) aseptic filling zones within ISO Class 7 (Grade C) clean rooms. Our design incorporated cascade pressure differentials (15 Pa between grades), HEPA filtration systems with 99.99% efficiency, and continuous environmental monitoring with 47 sampling points for particles, temperature, humidity, and viable organisms. The facility layout optimized material flow following ALCOA+ principles with dedicated corridors for personnel, materials, and waste to prevent cross-contamination. We designed a multi-stage water purification system producing 25 m³/hour Water for Injection (WFI) using reverse osmosis, electrode ionization, and multi-effect distillation, with continuous 80°C circulation loops preventing biofilm formation.

• Procurement & Supply Chain Support

  We conducted global supplier evaluation for critical aseptic filling lines, selecting European manufacturers for blow-fill-seal (BFS) machines and form-fill-seal systems ensuring container closure integrity. Our team procured specialized PP/PE co-extruded film for non-PVC bags meeting USP Class VI biocompatibility standards and identified three resin suppliers ensuring supply continuity. Quality control laboratory equipment procurement included HPLC, GC, atomic absorption spectroscopy, microbial testing equipment, and automated endotoxin testing systems. We established vendor qualification protocols ensuring GDP compliance for active pharmaceutical ingredients (sodium chloride, dextrose, electrolytes) and excipients sourced from approved DMF holders.

• Project Execution & Site Management:

  Our turnkey project management covered 24 months of execution coordinating civil works with specialized cleanroom construction, complex MEP installations, and phased equipment commissioning. We managed construction of 12,000 sq.m. GMP facility including separate production blocks for large volume parenterals, quality control laboratories with environmental chambers, microbiology labs with laminar flow cabinets, warehousing with temperature mapping (15-25°C), and administrative blocks. Clean room validation included installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ) for HVAC systems, water systems, and manufacturing equipment. We coordinated media fills (three consecutive successful batches) demonstrating aseptic process capability and implemented comprehensive documentation systems including batch manufacturing records, validation protocols, and deviation management systems.

• Compliance, Quality & Sustainability:

  IMARC developed 147 SOPs covering aseptic manufacturing, environmental monitoring, change control, deviation management, and CAPA systems aligned with WHO-GMP Annex 6 requirements. We conducted five mock regulatory inspections identifying and resolving 31 potential observations before official EDA inspection. Our team managed WHO Pre-qualification application documentation including site master files, manufacturing authorization, quality management system documentation, and product dossiers for four lead formulations. We established finished product testing protocols meeting USP sterility, pyrogen, particulate matter, and assay specifications. Workforce planning identified requirements for 180 personnel including production operators, quality control analysts, quality assurance specialists, and engineering support. We conducted comprehensive GMP training covering aseptic techniques, gowning procedures, contamination control, and data integrity principles.

Final Results

The facility achieved successful commissioning in 23 months with EDA manufacturing license approval within 6 months of completion. WHO-GMP certification was secured 8 months post-commissioning following successful regulatory inspection with zero critical observations. The plant now produces 100 Million IV bags annually across 12 SKUs with 94% capacity utilization.

Final CapEx of EGP 920 Million achieved 3.2% savings through optimized procurement and efficient project execution. The facility demonstrates exceptional quality metrics: zero sterility failures in first year (18 production batches per month), environmental monitoring compliance >99.7%, and water system meeting WFI specifications with no bioburden excursions.

Supply agreements with Egyptian Ministry of Health, major hospital chains, and private healthcare providers ensure stable demand. The facility received WHO Pre-qualification for Normal Saline and Ringer's Lactate formulations, enabling exports to 12 African countries generating $8.5 Million additional annual revenue.

Our energy-efficient design incorporating heat recovery from clean steam generation and optimized HVAC operations achieves 18% lower energy consumption versus industry benchmarks, saving EGP 4.2 Million annually. The project positioned the client as Egypt's leading parenteral manufacturer with expansion plans for specialized oncology infusions.